Shinpoong Pharmaceutical is strong on the news that Piramax’s COVID-19 global clinical phase 3 is underway.
As of 9:28 am on the 6th, Shinpoong Pharmaceutical is trading at 124,000 won, up 6,000 won (5.06%) from the previous day.
According to the FDA and an economic media in Korea, the Liverpool School of Tropical Medicine at the University of Liverpool in the UK confirmed the treatment effect of Pyramax on corona patients in Kenya and Burkina Faso, Africa. It was officially registered on (US clinical trial registration site) This clinical trial will start on the 8th (local time), and the target time for clinical completion is July 31, 2023.
This clinical trial will be conducted on 142 patients infected with both corona and malaria. Corona treatment effects were compared with the control group (71 people) who were prescribed the standard primary antimalarial drug’Artemer Lumepanthrin’ for 3 times a day and 3 days, and the experimental group who was prescribed’pyrronaridin altesunate’. Confirm.
The study will be jointly participated by the Bill & Melinda Gates Foundation, the US Centers for Disease Control and Prevention, the Kenya Institute of Medicine, and the Kenya Centers for Disease Control and Prevention.
– .
